pdf   xlsx method abbreviations

mUC - L1 - PDL1 positive, durvalumab plus tremelimumab , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.74 [0.59, 0.93]< 10%1 study (1/-)99.5 %NAnot evaluable crucial-
progression or deaths (PFS) 1.02 [0.62, 1.68]< 10%1 study (1/-)46.8 %NAnot evaluable important-
DOR 0.38 [0.19, 0.75]< 10%1 study (1/-)99.7 %NAnot evaluable non important-
objective responses (ORR) 0.94 [0.64, 1.39]> 10%1 study (1/-)38.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.